ADRB3 and autosomal dominant polycystic kidney disease: The β3‐AR‐selective blocker SR59230A reduces cAMP levels as well as kidney size, preserves renal parenchyma integrity and produces a trend toward functional recovery in a mouse model of ADPKD.